Navigation Links
Indevus Announces Management Changes
Date:6/12/2008

perating expenses and its R & D programs with the objective of rapidly aligning its cost structure to its revenue projections and R & D opportunities. When the Board has approved a revised operating plan, the Company will update its guidance for revenues and expenses. Other key Company priorities include non-dilutive finance options which include product out-license transactions and the monetization of its SANCTURA(R) and SANCTURA XR royalty streams and the retirement or restructuring of the Company's convertible debt which matures in July 2009.

As part of the realignment, the Company is also announcing that Thomas F. Farb, its president and chief operating officer and Kurt Lewis, its senior vice president, sales and marketing are leaving the Company to pursue other opportunities. Mr. Lewis' position has been filled by Nancy Bryan, vice president, global marketing, who becomes senior vice president, sales and marketing. Before joining Indevus, Ms. Bryan was senior vice president, head of commercial at Elan for the autoimmune franchise, vice president of marketing for men's health at Bayer Pharmaceuticals and held various positions at Merck and Glaxo Wellcome.

Dr. Cooper added, "I would like to thank Tom Farb and Kurt Lewis for their service to the Company. Tom was instrumental in our acquisition of Valera Pharmaceuticals and has provided excellent leadership as president. He played a key role in preparing the Company for the launch of NEBIDO which is now delayed and will assist us with the development of a revised operating plan during the next month. Kurt has led the successful launch of SUPPRELIN LA, increased market share for VANTAS, and has been instrumental in the pre-launch planning for VALSTAR and NEBIDO. We wish Tom and Kurt all the best in their new endeavors."

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat condit
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
2. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
3. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
4. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
5. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
6. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
7. Indevus Announces Allergan as New Partner for SANCTURA Brand
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... disease risks, the biological characteristics people care most about ... heightthe textbook example of a complex traitattributes like risk ... genetic and environmental influences, making it challenging to find ... typically mate two individuals that differ in key waysfor ... study their descendents, looking for genes that tend to ...
(Date:9/19/2014)... YORK , Sept. 19, 2014  An entire ... forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) – ... and legs, causing extreme muscle atrophy, weakness, and foot ... the US and millions worldwide. CMT is a progressive ... of their legs, requiring mobility devices such as leg ...
(Date:9/19/2014)... Florida , September 19, 2014 ... release latest developments, patents and results of studies and ... Eli Lilly and Company (NYSE: LLY ), ... Corporation (NASDAQ: CELG ) and Arena Pharmaceuticals ... a leader in developing prodrug therapeutics for the treatment ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
Breaking Biology Technology:Want to link genes to complex traits? Start with more diversity 2September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... , CINCINNATI , June 3 Kendle ... organization (CRO), today announced it is ranked a top CRO ... Survey. Kendle is the only CRO to be ranked consistently ... four years in the annual U.S. and European site surveys ...
... June 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... Wolff , executive vice president and CFO, will provide an update on the ... business strategy at two investor conferences during the month of June: , ... The Jefferies 2010 ...
... June 3 The John Theurer Cancer Center ... that will be presented at the American Society of Clinical ... – 8, 2010 in Chicago . Research highlights include ... lymphoma, the efficacy and safety of a new genetically engineered ...
Cached Biology Technology:Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 2Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 3Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences 2New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 2New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 3New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 4New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 5New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 6
(Date:9/21/2014)... Carbon dioxide emissions, the main contributor to global warming, are ... high of 40 billion tonnes. , The 2.5 per cent ... Global Carbon Project, which is co-led in the UK by ... the University of East Anglia and the College of Engineering, ... It comes ahead of the New York Climate Summit, where ...
(Date:9/21/2014)... recent years, new strains of bacteria have emerged that ... superbugs, including drug-resistant forms of tuberculosis and staphylococcus, infect ... least 23,000. Despite the urgent need for new treatments, ... in the past decade. , MIT engineers have now ... a gene-editing system that can disable any target gene, ...
(Date:9/21/2014)... MA -- Shellfish such as mussels and barnacles secrete ... or ship hulls, even underwater. Inspired by these natural ... materials that could be used to repair ships or ... their new waterproof adhesives, the MIT researchers engineered bacteria ... mussel proteins as well as a bacterial protein found ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Battling superbugs 2Battling superbugs 3Battling superbugs 4Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3
... (IUPAB) and Springer will launch the journal Biophysical ... is the new official journal of the IUPAB, ... societies with approximately 15,000 members. The entire IUPAB ... journal in order to demonstrate the close affiliation between ...
... football players who gain weight to add power to their ... diabetes and heart disease later in life, a new study ... and defensive linemen who underwent a battery of tests for ... at least three of five risk factors that indicate a ...
... flies snore, but rest assured that when you,re asleep ... January 2009 issue of the journal GENETICS ... City have shown that the circadian rhythms (sleep/wake cycles) ... of the same "cellular machinery" as that of humans. ...
Cached Biology News:Biophysical Reviews makes debut in 2009 2Athletes not spared from health risks of metabolic syndrome 2Athletes not spared from health risks of metabolic syndrome 3When it comes to sleep research, fruit flies and people make unlikely bedfellows 2
...
... robotic workstations is designed for laboratories with ... ideal automation platform for routine sample preparation ... improving throughput, process consistency and safety. ... allows you to control the robotic and ...
...
...
Biology Products: